MYC and medulloblastoma: Treatment with the orally bioavailable BRD4 inhibitor MK-8628 suppresses medulloblastoma cell proliferation and induces apoptosis by reducing MYC expression, and MK-8628 suppresses medulloblastoma tumor progression in preclinical models [48].